These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 20810155

  • 1. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
    Roufosse F, de Lavareille A, Schandené L, Cogan E, Georgelas A, Wagner L, Xi L, Raffeld M, Goldman M, Gleich GJ, Klion A.
    J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
    [Abstract] [Full Text] [Related]

  • 2. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB, Sheikh J, Singh A.
    Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
    [Abstract] [Full Text] [Related]

  • 3. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
    Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, Rothenberg ME, Roufosse F, Sajous MH, Sheikh J, Simon D, Simon HU, Stein ML, Wardlaw A, Weller PF, Klion AD.
    J Allergy Clin Immunol; 2009 Dec; 124(6):1319-25.e3. PubMed ID: 19910029
    [Abstract] [Full Text] [Related]

  • 4. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
    Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ, Mepolizumab HES Study Group.
    N Engl J Med; 2008 Mar 20; 358(12):1215-28. PubMed ID: 18344568
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. CD3-CD4+ Lymphocytic Variant Hypereosinophilic Syndrome: Diagnostic Tools Revisited.
    Carpentier C, Schandené L, Dewispelaere L, Heimann P, Cogan E, Roufosse F.
    J Allergy Clin Immunol Pract; 2021 Jun 20; 9(6):2426-2439.e7. PubMed ID: 33545400
    [Abstract] [Full Text] [Related]

  • 7. Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study.
    Gleich GJ, Roufosse F, Chupp G, Faguer S, Walz B, Reiter A, Yancey SW, Bentley JH, Steinfeld J, HES Mepolizumab Study Group.
    J Allergy Clin Immunol Pract; 2021 Dec 20; 9(12):4431-4440.e1. PubMed ID: 34389506
    [Abstract] [Full Text] [Related]

  • 8. Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.
    Rothenberg ME, Roufosse F, Faguer S, Gleich GJ, Steinfeld J, Yancey SW, Mavropoulou E, Kwon N, HES Mepolizumab Study Group.
    J Allergy Clin Immunol Pract; 2022 Sep 20; 10(9):2367-2374.e3. PubMed ID: 35568330
    [Abstract] [Full Text] [Related]

  • 9. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
    Busse WW, Ring J, Huss-Marp J, Kahn JE.
    J Allergy Clin Immunol; 2010 Apr 20; 125(4):803-13. PubMed ID: 20371394
    [Abstract] [Full Text] [Related]

  • 10. Eosinophils affect functions of in vitro-activated human CD3-CD4+ T cells.
    Harfi I, Schandené L, Dremier S, Roufosse F.
    J Transl Med; 2013 May 06; 11():112. PubMed ID: 23642304
    [Abstract] [Full Text] [Related]

  • 11. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.
    Kuang FL, Fay MP, Ware J, Wetzler L, Holland-Thomas N, Brown T, Ortega H, Steinfeld J, Khoury P, Klion AD.
    J Allergy Clin Immunol Pract; 2018 May 06; 6(5):1518-1527.e5. PubMed ID: 29751154
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Eosinophilia Associated With CD3-CD4+ T Cells: Characterization and Outcome of a Single-Center Cohort of 26 Patients.
    Carpentier C, Verbanck S, Schandené L, Heimann P, Trépant AL, Cogan E, Roufosse F.
    Front Immunol; 2020 May 06; 11():1765. PubMed ID: 32849632
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mepolizumab in eosinophilic disorders.
    Abonia JP, Putnam PE.
    Expert Rev Clin Immunol; 2011 Jul 06; 7(4):411-7. PubMed ID: 21790283
    [Abstract] [Full Text] [Related]

  • 16. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
    Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, Beck LA, Boyce JA, Filipovich AH, Villanueva JM, Sutton SA, Assa'ad AH, Rothenberg ME.
    J Allergy Clin Immunol; 2004 Jan 06; 113(1):115-9. PubMed ID: 14699394
    [Abstract] [Full Text] [Related]

  • 17. Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome.
    Reiter A, Lefevre G, Cid MC, Kwon N, Mavropolou E, Yancey SW, Steinfeld J.
    Front Immunol; 2022 Jan 06; 13():840974. PubMed ID: 35493455
    [Abstract] [Full Text] [Related]

  • 18. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008 Jan 06; 9(2):125-30. PubMed ID: 18298130
    [Abstract] [Full Text] [Related]

  • 19. The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype.
    Lefèvre G, Copin MC, Staumont-Sallé D, Avenel-Audran M, Aubert H, Taieb A, Salles G, Maisonneuve H, Ghomari K, Ackerman F, Legrand F, Baruchel A, Launay D, Terriou L, Leclech C, Khouatra C, Morati-Hafsaoui C, Labalette M, Borie R, Cotton F, Gouellec NL, Morschhauser F, Trauet J, Roche-Lestienne C, Capron M, Hatron PY, Prin L, Kahn JE, French Eosinophil Network.
    Medicine (Baltimore); 2014 Oct 06; 93(17):255-266. PubMed ID: 25398061
    [Abstract] [Full Text] [Related]

  • 20. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome.
    Kim S, Marigowda G, Oren E, Israel E, Wechsler ME.
    J Allergy Clin Immunol; 2010 Jun 06; 125(6):1336-43. PubMed ID: 20513524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.